Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 83 points (-0.5%) at 16,448 as of Tuesday, May 6, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,223 issues advancing vs. 1,760 declining with 164 unchanged. The Health Services industry currently sits down 0.1% versus the S&P 500, which is down 0.4%. A company within the industry that fell today was Fresenius Medical Care AG & Co. KGaA ( FMS), up 2.8%. Top gainers within the industry include WellCare Health Plans ( WCG), up 5.4%, CareFusion ( CFN), up 1.7%, Hologic ( HOLX), up 1.6% and Varian Medical Systems ( VAR), up 0.9%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Grifols ( GRFS) is one of the companies pushing the Health Services industry lower today. As of noon trading, Grifols is down $0.90 (-2.2%) to $40.94 on heavy volume. Thus far, 574,917 shares of Grifols exchanged hands as compared to its average daily volume of 606,600 shares. The stock has ranged in price between $40.55-$41.57 after having opened the day at $41.49 as compared to the previous trading day's close of $41.84. Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. Grifols has a market cap of $14.3 billion and is part of the health care sector. The company has a P/E ratio of 41.2, above the S&P 500 P/E ratio of 17.7. Shares are up 15.8% year-to-date as of the close of trading on Monday. Currently there are 4 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Grifols as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Grifols Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
2. As of noon trading, HCA Holdings ( HCA) is down $0.28 (-0.5%) to $52.07 on light volume. Thus far, 856,319 shares of HCA Holdings exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $51.92-$52.84 after having opened the day at $52.25 as compared to the previous trading day's close of $52.35. HCA Holdings, Inc., through its subsidiaries, provides health care services. HCA Holdings has a market cap of $23.0 billion and is part of the health care sector. The company has a P/E ratio of 14.7, below the S&P 500 P/E ratio of 17.7. Shares are up 9.7% year-to-date as of the close of trading on Monday. Currently there are 15 analysts that rate HCA Holdings a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates HCA Holdings as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and increase in net income. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. Get the full HCA Holdings Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
1. As of noon trading, Boston Scientific ( BSX) is down $0.15 (-1.1%) to $12.92 on light volume. Thus far, 4.1 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 12.8 million shares. The stock has ranged in price between $12.90-$13.08 after having opened the day at $13.04 as compared to the previous trading day's close of $13.07. Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. Boston Scientific has a market cap of $17.0 billion and is part of the health care sector. Shares are up 8.7% year-to-date as of the close of trading on Monday. Currently there are 11 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 10 rate it a hold. TheStreet Ratings rates Boston Scientific as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, solid stock price performance and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Boston Scientific Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).
